1453 - PBP2, PBP2a and PBP4 Clone-specific Polymorphisms are not Associated to Ceftaroline (CPT) Susceptibility in Chilean Clinical Isolates of Methicillin-Resistant Staphylococcus aureus (MRSA)

The ePoster content is available to users who are logged in.<br><br>Please log in and then come back here to use this button.

Presenting Author(s)

Maria de los Angeles Spencer

Investigator
GeRM Lab, ICIM, Universidad del Desarrollo
Santiago, Region Metropolitana, Chile
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Co-Author(s)

JM

José Rodrigo Martinez

PhD student
GeRM Lab, ICIM, Universidad del Desarrollo
Santiago, Region Metropolitana, Chile
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
LR

Lina María Rivas

Investigator
GeRM Lab, ICIM, Universidad del Desarrollo
Santiago, Region Metropolitana, Chile
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Mr

Marcelo rojas

PhD student
Bioinformatics, ICIM, Universidad del Desarrollo
Santiago, Region Metropolitana, Chile
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
RR

Rafael Rios

Assistant Professor
Universidad El Bosque
Bogota, Distrito Capital de Bogota, Colombia
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
AD

An Q. Dinh

Research Engineer
Center for Antimicrobial Resistance and Microbial Genomics, UTHealth, Houston, TX,
Houston, Texas
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Lorena Diaz

Associate Professor
Universidad Del Desarrollo
Santiago, Region Metropolitana, Chile
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
JR

Jinnethe Reyes

Postdoctoral fellow
Universidad El Bosque
Bogota, Distrito Capital de Bogota, Colombia
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Blake M. Hanson

Assistant Professor
The University of Texas Health Science Center
Houston, Texas
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
PG

Patricia Garcia

Physician
Pontificia Universidad Catolica de Chile
Santiago, Region Metropolitana, Chile
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
CA

Cesar A. Arias

Professor
Houston Methodist Hospital, Center for Infectious Diseases Research, Houston Methodist Research Institute
Houston, Texas
Disclosure: Entasis Therapeutics (Scientific Research Study Investigator)MeMed (Scientific Research Study Investigator)Merck (Grant/Research Support)
JM

Jose M. Munita

Associate Professor
Millennium Initiative for Collaborative Research on Bacterial Resistance (MICROB-R), Genomics and Resistant Microbes (GeRM) Group. Clínica Alemana de Santiago, Universidad del Desarrollo School of Medicine
Santiago, Region Metropolitana, Chile
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Background: CPT is a last-generation cephalosporin active against MRSA due to its affinity for PBP2a. CPT-resistance (CPT-R) is well-described, with mutations in the active transpeptidase domain of PBP2a associated to high-level resistance. The accumulation of changes in the non-penicillin-binding domain of PBP2a has been linked to elevations of the minimal inhibitory concentration (MIC) to CPT to levels around 2-4ug/mL. PBP4 and PBP2 have also been implicated as potentially relevant mecA-independent mechanisms of CPT-R. We recently reported high rates of CPT-non-susceptibility in clinical MRSA strains from Chile. However, the mutational landscape of PBPs in clinical MRSA isolates from Chile and its relation to CPT susceptibility has not been assessed.

Methods: We analyzed 180 MRSA isolates collected from 2000-2018 in Santiago, Chile. Identification was confirmed by MALDI-TOF and methicillin resistance with cefoxitin disk-diffusion. CPT susceptibility was performed by BMD following CLSI-2019 guidance. Whole-genome sequencing was performed for all isolates; the mutational profile of PBPs was determined using reference sequences for PBP2 (AGY89563.1), PBP2a (NG_047938.1) and PBP4 (X91786.1).

Results: All isolates were phenotypically-confirmed MRSA and harbored mecA. The MIC₅₀/MIC₉₀ by BMD was 2/2μg/dL; only 71 (39%) isolates were CPT-susceptible (MIC <1µg/mL). Most isolates belonged to ST5/SCCmecI (70%,126/180), ST105/SCCmecII (10%,18/180) and ST8/SCCmecIV (5%, 9/180). All ST5/SCCmecI isolates carried the mutations in PBP2 (Y156D), PBP2a (M122I and E150K), and PBP4 (T189S, L234H, and T409A); CPT-susceptibility among ST5/SCCmecI was only 22%. On the other hand, all ST105/SCCmecII isolates had mutations in PBP2 (S707L) and PBP4 (T189S, L234H, and T409A) and exhibited a higher CPT-susceptibility rate (67%). All 9 isolates belonging to the ST8/SCCmecIV lineage harbored a non-coding mutation in PBP2a (g-6t) and the previously observed L234H change in PBP4. Importantly, no association between specific polymorphisms and MIC to CPT was found.Table 1. PBPs mutations compared to CPT MICs by MLST and SCCmec

Conclusion: Changes in the studied PBPs were frequent among MRSA circulating in Chile and were conserved among different genetic backgrounds. However, these changes were not associated with the level of CPT MIC among these isolates.